(Q50921699)

25 March 2018

title

The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury. (English)

1 reference

25 March 2018

0 references

0 references

1 reference

Hagenbach U

1

1 reference

25 March 2018

Luz S

2

1 reference

25 March 2018

Ghafoor N

3

1 reference

25 March 2018

Berger JM

4

1 reference

25 March 2018

Grotenhermen F

5

1 reference

25 March 2018

Brenneisen R

6

1 reference

25 March 2018

Mäder M

7

1 reference

25 March 2018

publication date

17 October 2006

1 reference

25 March 2018

published in

Spinal Cord

1 reference

25 March 2018

volume

45

1 reference

25 March 2018

page(s)

551-562

1 reference

25 March 2018

issue

8

1 reference

25 March 2018

https://scigraph.springernature.com/pub.10.1038/sj.sc.3101982

exact match

0 references

cites work

The perceived effects of smoked cannabis on patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

Effect of cannabinoids on spasticity and ataxia in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

Nabilone in the treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

Pharmacokinetics and pharmacodynamics of cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

Motor actions of cannabinoids in the basal ganglia output nuclei

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

Tetrahydrocannabinol for tremor in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

Are oral cannabinoids safe and effective in refractory neuropathic pain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

Effect of benzopyranoperidine, a Δ-9-THC congener, on pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

Marihuana as a therapeutic agent for muscle spasm or spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

7 January 2021

Interrater reliability of a modified Ashworth scale of muscle spasticity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

7 January 2021

Performance profiles of the functional independence measure.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

7 January 2021

Continuous performance tests: a comparison of modalities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

7 January 2021

Trends in the pathophysiology and pharmacotherapy of spasticity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

7 January 2021

Endocannabinoids control spasticity in a multiple sclerosis model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

7 January 2021

Effects of Moderate and High Doses of Marihuana on Thermal Pain: A Sensory Decision Theory Analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101982

7 January 2021

Identifiers

DOI

10.1038/SJ.SC.3101982

1 reference

25 March 2018

PubMed ID

17043680

1 reference

25 March 2018